Thrombotic microangiopathy: Thrombocytopenia and haemolytic anaemia;Trombotische microangiopathie: Trombocytopenie en hemolytische anemie

Nederlands Tijdschrift voor Geneeskunde

Volumn 146, Issue 49, 2002, Pages 2343-2347

  Kater, A P ^a   Van Der Lelie, J ^a   Levi, M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; VEROTOXIN; VON WILLEBRAND FACTOR;

ARTICLE; CLINICAL FEATURE; DISEASE COURSE; ENZYME ACTIVITY; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION;

ADAM PROTEINS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; METALLOENDOPEPTIDASES; PLASMA EXCHANGE; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SENSITIVITY AND SPECIFICITY; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 0037038854     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001;60:831-46.
2. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-84.
3. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-94.
4. Gerritsen HE, Turecek PL, Schwarz HP, Lammle H, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: A tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999;82:1386-9.
5. Kappers-Klunne MC, Meulen JH van der, Holdrinet RS, Meer J van der, Wijermans PW, Brand A. Trombotische trombocytopenische purpura in 13 Nederlandse centra: Behandeling en beloop. Ned Tijdschr Geneeskd 1997;141:1192-6.
6. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96:1223-9.
7. Dundas S, Murphy J, Soutar RL, Jones GA, Hutchinson SJ, Todd WT. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 1999;354:1327-30.
8. Plas RM van der, Schiphorst ME, Huizinga EG, Hene RJ, Verdonck LF, Sixma JJ, et al. Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999;93:3798-802.
9. Gordon LI, Kwaan HC. Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Semin Thromb Hemost 1999;25:217-21.
10. Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000;132:794-9.
11. McDonald SP, Shanahan EM, Thomas AC, Roxby DJ, Beroukas D, Barbara JA. Quinine-induced hemolytic uremic syndrome. Clin Nephrol 1997;47:397-400.
12. Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Frequency, clinical features, and long-term outcomes. Ann Intern Med 2001;135:1047-51.
13. Musio F, Bohen EM. Yuan CM, Welch PG. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 1998;28:1-19.
14. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine 1998;77:195-207.
15. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001;98:2730-5.
16. Moore JC, Hayward CP, Warkentin TE, Kelton JG. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001;98:1842-6.
17. Noris M, Ruggenenti P, Perna A, Orisio S, Caprioli J, Skerka C, et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J Am Soc Nephrol 1999;10:281-93.
18. Rock GA, Shumak KR, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393-7.
19. Veltman GA, Brand A, Leeksma OC, Bosch GJ ten, Krieken JR van, Briat E. The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura. Ann Hematol 1995;70:231-6.
20. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001;413:488-94.
21. Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int 1995;48:2-19.
22. Kar NCAJ van de, Heuvelink AE, Boer E de, Monnens LAH. Infecties met verocytotoxine-producerende Escherichia coli en het hemolytisch-uremisch syndroom. Ned Tijdschr Geneeskd 1996;140:134-7.
23. Shefer AM, Koo D, Werner SB, Mintz ED, Baron R, Wells JG, et al. A cluster of Escherichia coli O157:H7 infections with the hemolytic-uremic syndrome and death in California. A mandate for improved surveillance. West J Med 1996;165:15-9.
24. Heuvelink AE, Loo DMWM te, Monnens LAH. Het hemolytischuremisch syndroom op de kinderleeftijd. Ned Tijdschr Geneeskd 2001;145:620-5.
25. Kater AP, Westermann AM, Groot MR de, Borne AE von dem, Kuijper EJ. Toxin-mediated haemolytic uraemic syndrome without diarrhoea. J Intern Med 2000;248:263-5.
26. Starr M, Bennett-Wood V, Bigham AK, Koning-Ward TF de, Bordun AM, Lightfoot D, et al. Hemolytic-uremic syndrome following urinary tract infection with enterohemorrhagic Escherichia coli: Case report and review. Clin Infect Dis 1998;27:310-5.
27. Pollard DR, Johnson WM, Lior H, Tyler SD, Rozee MD. Rapid and specific detection of verotoxin genes in Escherichia coli by polymerase chain reaction. J Clin Microbiol 1990;28:540-5.
28. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000;342:1930-6.
29. Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, et al. Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry. J Clin Oncol 1989;7:781-9.
30. Lelie H van der, Baars JW, Rodenhuis S, Dijk MA van, Glas-Vos CW de, Thomas BL, et al. Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. Cancer 1995;76:2338-42.
31. Fuge R, Bird JM, Fraser A, Hart D, Hunt L, Cornish JM, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001;113:58-64.
32. Walfe JA, McCann RL, Sanfilippo F. Cyclosporine-associated microangiopathy in renal transplantation: A severe but potentially reversible form of early graft injury. Transplantation 1986;41:541-4.
33. Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999;159:2524-8.
34. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR. et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000:342:1773-7.
35. Sutor GC, Schmidt RE, Albrecht H. Thrombotic microangiopathies and HIV infection: Report of two typical cases, features of HUS and TTP, and review of the literature. Infection 1999;27:12-5.
36. Bakir AA, Bazilinski N, Dunea G. Transient and sustained recovery from renal shutdown in accelerated hypertension. Am J Med 1986;80:172-6.